Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00781612
Title A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

Therapies

Ado-trastuzumab emtansine + Trastuzumab

Ado-trastuzumab emtansine + Paclitaxel

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Docetaxel

Ado-trastuzumab emtansine + Capecitabine

Ado-trastuzumab emtansine + Pertuzumab

Age Groups: senior | child | adult
Covered Countries USA | CAN


No variant requirements are available.